M&A / Deals Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn Pharmaceutical Business ReviewThe value includes a $1.55bn upfront payment and as much as $1.1bn in regulatory and commercial milestone payments.Rare DiseaseRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) Pharmaceutical Business Review The value includes a $1.55bn upfront payment and as much as $1.1bn in regulatory and commercial milestone payments. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ASCO26: AZ triplet makes waves in frontline liver cancerNext: ASCO26: Symptom-tracking app helps advanced cancer patients Related Stories M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026 M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026
